Earlier this month, UK pharmaceutical and “consumer healthcare” conglomerate GSK took a look at its Lucozade and Ribena brands, and set itself a choice: Does it sell the two, or does it look at setting up an investment programme? Richard Corbett considers the firm’s dilemma.

Stay informed for just £1! *

Get access to unbiased and data-driven news with a subscription to Just Drinks.

What’s included in your subscription:

  • Unlimited access to Just Drinks content including daily global news, in-depth analysis, and interviews with C-suite executives
  • Unbeatable coverage of categories from beer, wine and spirits to soft drinks and hot
    beverages
  • Unrivalled drinks industry comment from Dean Best, Jessica Broadbent and leading sector specialists

Have a Subscribtion Sign in

Get help with subscribing or signing in

*30-day digital subscription for £1. Available to new subscribers only